Author: healthprofessionalradio

Dr. Rakesh Suri, President and Chief Medical Officer at Fountain Life, a preventative health and longevity company discusses Fountain Life’s unique data-driven approach that enables finding illnesses, including cancer, cardiac, metabolic, and neurodegenerative disease, early before they can cause harm. The company has three open U.S. sites in Naples, FL, Dallas, TX, and White Plains, NY. Dr. Suri talks about how they are planning to transform global healthcare from reactive to proactive not only across the United States but globally.

Dr. Jeff Gudin, MD, Sr. Medical Advisor, Drug Monitoring and Toxicology at Quest Diagnostics discusses a report that he co-authored that found that one in two patients (49%) showed signs of prescription drug misuse in 2021 including use of amphetamines (stimulants, such as Adderall) which surged 5-fold over the last decade. He shares his views on avenues out of the drug crisis and talks about the updated CDC opioid guidance.

Returning guest, Dr. Derek Wallace, MBBS, Vice President and Global Dengue Program Head at Takeda discusses the dengue program and the European Commission (EC) approval of the company’s dengue vaccine, QDENGA ® (TAK-003), for the prevention of dengue disease caused by any serotype in individuals from four years of age in the European Union (EU).

Dr. Holly Johnson, Director of Medical Information at Myriad Mental Health discusses the GeneSight test that analyzes genes to see how a person may respond to commonly prescribed mental health medications. She also talks about a recent survey looking at the relationship between primary care physicians and their patients when it comes to mental health issues.

Graft-versus-host disease, also known as GVHD, is a life-threatening condition that can occur after an allogeneic stem cell transplant, or the transfer of stem cells from a donor, where the donated cells initiate an immune response and attack the transplant recipient’s organs, leading to significant morbidity and mortality. To help support those living with GVHD, Incyte created the Incyte Ingenuity Awards in GVHD, which aims to support the GVHD community in the U.S. by funding two novel initiatives that address challenges faced by people impacted by GVHD, including patients, caregivers, and healthcare providers.

Dr. Antonio Anzueto, Professor of Medicine and Section Chief of Pulmonary at South Texas Veterans Healthcare System, an affiliated Institution with the University of Texas Health San Antonio, discusses the 2023 Global Obstruction Lung Disease (GOLD)  Report that recommends long-acting muscarinic antagonist (LAMA), long-acting beta agonist (LABA), or LAMA+LABA therapy  as a first-line treatment  for most patients with COPD, regardless of exacerbation risk.

Sangamo Therapeutics is working to translate groundbreaking science into genomic cures. Jason Fontenot, Senior Vice President and Chief Scientific Officer of Sangamo, discusses cutting-edge science on the frontiers of genomic medicine, and promising treatments for genomic diseases once thought to be intractable.

Dr. Robert Risinger, Chief Medical Officer, Neuroscience at BioXcel Therapeutics, a biopharmaceutical company that uses artificial intelligence (AI) to identify drug targets and develop drugs in neuroscience and immuno-oncology, discusses the company’s lead product, IGALMI™ (dexmedetomidine), a sublingual film used to treat agitation associated with schizophrenia or bipolar disorder and three more compounds in earlier phases of development: BXCL501, BXCL502, and +BXCL501.

Jamie McCoy, General Manager of Theranostics and Radiotherapeutics at GE HealthCare discusses theranostics and how it is changing the treatment of prostate cancer and what impact this will have on patients.

Dr. Allison McMullen, PhD, Scientific Partner for Molecular Diagnostics at Roche Diagnostics discusses a survey that shows that many Americans are confused by the differences between PCR tests and rapid antigen tests and when to use them. She talks about the importance of early diagnosis to differentiate between similar-looking respiratory viruses (including flu, COVID, and RSV), the available testing options, the latest advances in diagnostics, and additional findings from the new survey.